Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Disoproxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | POLG | P54098 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Disoproxil SCHEMBL16237284 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL985120 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL343783 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL3234290 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL2670560 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL18190782 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL40021 | 1.00 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL3113154 | 0.97 | FAP (0.94) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL1560984 | 0.97 | FAP (0.94) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL497677 | 0.95 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107341-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026102058-A1 | METHODS FOR TREATING CHRONIC HEPATITIS B INFECTION AND RELATED FORMULATIONS | TUNE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3837366-B1 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4692236-A1 | THERMOPLASTIC RESIN COMPOSITION HAVING EXCELLENT HARDNESS, DISCOLORATION RESISTANCE, AND IMPACT RESISTANCE, AND MOLDED ARTICLE COMPRISING SAME | Samyang Corporation (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20260034339-A1 | SUBCUTANEOUS BIODEGRADABLE RESERVOIR DEVICE | RES TRIANGLE INST (US) | 2026-02-05 | — | — | US | claimed |
| EP-4680243-A1 | METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | claimed |
| US-12515027-B2 | Subcutaneous biodegradable reservoir device | RESEARCH TRIANGLE INSTITUTE (US) | 2026-01-06 | — | — | US | claimed |
| WO-2025262623-A1 | METHOD OF TREATING HBV/HIV COINFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-12-26 | — | — | WO | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-3976613-A1 | AZEPINES AS HBV CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | claimed |
| CN-114279052-A | Multi-split air conditioning system | 青岛海信日立空调系统有限公司 | 2022-04-05 | — | — | CN | claimed |
| EP-3969588-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | VIR Biotechnology, Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3965751-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2022-03-16 | — | — | EP | claimed |
| CN-111734380-B | Rapid prediction method for horizontal well multistage fracturing fracture propagation form | 西南石油大学 | 2022-03-11 | — | — | CN | claimed |
| CN-114126654-A | Para-aminohippuric acid (PAH) as a kidney protective substance | 同位素技术慕尼黑有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-114126628-A | Compositions and methods for treating Hepatitis B Virus (HBV) infection | 维尔生物科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2022-02-24 | — | — | US | claimed |
| US-20220025021-A1 | ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-01-27 | — | — | US | claimed |
| EP-3941921-A1 | THERAPEUTIC METHODS FOR TREATING HEPATITIS B | Arbutus Biopharma Corporation (CA) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | FAP 19/4885CYP3A4 3207/4885CYP2D6 2150/4885 |
| US-20260034339-A1 | SUBCUTANEOUS BIODEGRADABLE RESERVOIR DEVICE | CUTA, CD209, SLC19A1 | FAP 2732/4885CYP3A4 3162/4885CYP2D6 2538/4885 |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HAVCR2, HLA-B, HDGF | FAP 1447/4885CYP3A4 3704/4885CYP2D6 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.